December 15, 2023 06:33 AM ESTUpdated 09:01 AM
Deals

Pfiz­er picks up ear­ly-stage ADC can­di­date cleared for sol­id tu­mor tri­als

Amber Tong

Just days af­ter clos­ing its Seagen ac­qui­si­tion, Pfiz­er has struck a deal to ex­pand its an­ti­body-drug con­ju­gate port­fo­lio even fur­ther.

Nona Bio­sciences …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

A service from the Financial Times